Fred Telling - 11 Dec 2025 Form 4/A - Amendment Insider Report for ORAGENICS INC (OGEN)

Role
Director
Signature
/s/ Julio C. Esquivel as Attorney-In-Fact for Fred Telling
Issuer symbol
OGEN
Transactions as of
11 Dec 2025
Net transactions value
-$198
Form type
4/A - Amendment
Filing time
22 Jan 2026, 13:04:30 UTC
Date Of Original Report
15 Dec 2025
Previous filing
09 Dec 2024
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Telling Fred Director 9015 TOWN CENTER PARKWAY, SUITE 143, LAKEWOOD RANCH /s/ Julio C. Esquivel as Attorney-In-Fact for Fred Telling 22 Jan 2026 0001382225

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction OGEN Common Stock Sale $198 -210 -18% $0.9446 948 12 Dec 2025 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OGEN Non-Employee Director Option (Right to Buy) Award $0 +125,000 $0.000000 125,000 11 Dec 2025 Common Stock 125,000 $0.9300 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.9440 to $0.9451. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F2 This Amendment is being filed to correct the amount of securities beneficially owned. The Issuer effected a 1-for-30 reverse stock split of its outstanding common stock, which was not reflected on the prior Form 4.
F3 Represents an award of options to purchase shares of the Company's Common Stock under the Company's 2021 Equity Incentive Plan, as amended, pursuant to the Company's non-employee director compensation program. The options vest immediately. The option exercise price is the Company's closing price on the date of grant.